A proliferation‐inducing ligand–mediated anti‐inflammatory response of astrocytes in multiple sclerosis

The two related tumor necrosis factor members a proliferation‐inducing ligand (APRIL) and B‐cell activation factor (BAFF) are currently targeted in autoimmune diseases as B‐cell regulators. In multiple sclerosis (MS), combined APRIL/BAFF blockade led to unexpected exacerbated inflammation in the central nervous system (CNS) of patients. Here, we investigate the role of the APRIL/BAFF axis in the CNS.

[1]  M. Dyer,et al.  CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. , 2017, Cancer research.

[2]  S. Ludwin,et al.  Astrocytes in multiple sclerosis , 2016, Multiple sclerosis.

[3]  S. LeVine.  Albumin and multiple sclerosis , 2016, BMC Neurology.

[4]  Istvan Pirko,et al.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque , 2015, Annals of neurology.

[5]  Control of autoimmune CNS inflammation by astrocytes , 2015, Seminars in Immunopathology.

[6]  W. Brück,et al.  Cell type-specific Nrf2 expression in multiple sclerosis lesions , 2015, Acta Neuropathologica.

[7]  X. Montalban,et al.  ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis , 2015, Journal of the Neurological Sciences.

[8]  J. Passweg,et al.  Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow , 2015, Leukemia.

[9]  H. Weiner,et al.  Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation , 2014, Nature Medicine.

[10]  L. Kappos,et al.  Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial , 2014, The Lancet Neurology.

[11]  Amit Bar-Or,et al.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases , 2014, Nature.

[12]  H. Hess,et al.  Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis , 2014, Journal of Neuroimmunology.

[13]  A. Wu,et al.  Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse , 2012, Journal of Clinical Immunology.

[14]  L. Hsieh‐Wilson,et al.  A sulfated carbohydrate epitope inhibits axon regeneration after injury , 2012, Proceedings of the National Academy of Sciences.

[15]  M. Goldman,et al.  Interleukin-10 , 2012, BioDrugs.

[16]  H. Lassmann,et al.  Review: The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis , 2011, Neuropathology and applied neurobiology.

[17]  K. Krause,et al.  Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. , 2011, Blood.

[18]  D. Richman,et al.  Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice , 2011, Journal of the Neurological Sciences.

[19]  T. Owens,et al.  Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease , 2011, Glia.

[20]  J. Monroe,et al.  B‐cell targeted therapies in human autoimmune diseases: an updated perspective , 2010, Immunological reviews.

[21]  G. Cavaletti,et al.  Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis , 2010, Journal of Neuroimmunology.

[22]  B. Song,et al.  Reactive Astrocytes Form Scar-Like Perivascular Barriers to Leukocytes during Adaptive Immune Inflammation of the CNS , 2009, The Journal of Neuroscience.

[23]  S. Miller,et al.  Astrocytes in multiple sclerosis: A product of their environment , 2008, Cellular and Molecular Life Sciences.

[24]  Anna C. Williams,et al.  Astrocytes—Friends or foes in multiple sclerosis? , 2007, Glia.

[25]  R. Jonsson,et al.  A Proliferation‐inducing Ligand (APRIL) is Expressed by Astrocytes and is Increased in Multiple Sclerosis , 2007, Scandinavian journal of immunology.

[26]  J. Tschopp,et al.  Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. , 2007, Blood.

[27]  Ravi V. Bellamkonda,et al.  CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension , 2005, Molecular and Cellular Neuroscience.

[28]  M. Hahne,et al.  Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation , 2005, Cell Death and Differentiation.

[29]  J. Tschopp,et al.  Identification of proteoglycans as the APRIL-specific binding partners , 2005, The Journal of experimental medicine.

[30]  A. Rosenwald,et al.  BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma , 2005, The Journal of experimental medicine.

[31]  H. M. Geller,et al.  Chondroitin 6‐sulphate synthesis is up‐regulated in injured CNS, induced by injury‐related cytokines and enhanced in axon‐growth inhibitory glia , 2005, The European journal of neuroscience.

[32]  Y. Richard,et al.  Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor , 2004, Oncogene.

[33]  J. Chroboczek,et al.  Heparan sulfate proteoglycan mediates the selective attachment and internalization of serotype 3 human adenovirus dodecahedron. , 2004, Virology.

[34]  R. Ransohoff,et al.  Expression of Chemokine Receptors CCR1 and CCR5 Reflects Differential Activation of Mononuclear Phagocytes in Pattern II and Pattern III Multiple Sclerosis Lesions , 2004, Journal of neuropathology and experimental neurology.

[35]  D. Lawrence,et al.  APRIL-Deficient Mice Have Normal Immune System Development , 2004, Molecular and Cellular Biology.

[36]  P. Schneider,et al.  BAFF AND APRIL: a tutorial on B cell survival. , 2003, Annual review of immunology.

[37]  J. Fawcett,et al.  Chondroitin sulphate proteoglycans in the central nervous system: changes and synthesis after injury. , 2003, Biochemical Society transactions.

[38]  M. Belting.  Heparan sulfate proteoglycan as a plasma membrane carrier. , 2003, Trends in biochemical sciences.

[39]  David Gray,et al.  B cells regulate autoimmunity by provision of IL-10 , 2002, Nature Immunology.

[40]  J. Tschopp,et al.  BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF , 2001, Science.

[41]  Tom Boone,et al.  APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity , 2000, Nature Immunology.

[42]  Jae-Wook Oh,et al.  Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor , 1999, The Journal of Neuroscience.

[43]  X. Bai,et al.  Developmental changes in heparan sulfate expression: in situ detection with mAbs , 1992, The Journal of cell biology.

[44]  R. Riopelle,et al.  Characterization of glycosaminoglycans produced by primary astrocytes in vitro , 1991, Glia.